- Who We Are and What We Do
- Research Projects
- HIV Vaccine Trials Unit (HVTU)
- Penn Center for AIDS Research (CFAR)
- Risk Assessment Battery (RAB)
- Community Advisory Board
- Contact Us
- Support Our Work
- Follow Us on Twitter
Previous and Closed Studies
A Multi-center, Double-Blind, Randomized, Placebo-Controlled Phase II Proof-of-Concept Study to Evaluate the Safety and Efficacy of a 3-Dose Regimen of the Merck Adenovirus Serotype 5 HIV-1 Vaccine gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) in Adults at High Risk of HIV-1 Infection
Primary Safety: To demonstrate that intramuscular injection of the Merck Adenovirus Serotype 5 HIV-1 gag/pol/nef Vaccine (MRKAd5 HIV-1 gag/pol/nef) is generally safe and well tolerated in 18 to 45 year old HIV-1 seronegative adults with baseline Ad5 titers < 200.
Primary Efficacy: To demonstrate that intramuscular injection of the MRKAd5 HIV-1 gag/pol/nef vaccine (a) reduces the proportion of subjects who acquire HIV-1 infection and/or (b) results in a decrease in the HIV-1 viral load set-point (HIV-1 RNA at ~ 3 months post-diagnosis), in subjects who become HIV-1 infected, relative to placebo recipients.
A Phase I clinical trial to evaluate the safety and immunogenicity of PENNVAX-B (gag, pol, env) given alone, with IL-12 DNA, or with a dose escalation of IL-15 DNA, in healthy, HIV-1 - uninfected adult participants.
To assess the safety and tolerability of a multigene HIV DNA vaccine (gag, pol, env) with or without co-administration of IL-12 DNA or IL-15 DNA in a cohort of HIV-uninfected healthy adults.
To evaluate the safety and tolerability of IL-15 DNA (escalating doses of 0.8 mg and 2 mg) with co-administration of 6 mg of a multigene HIV DNA vaccine (gag, pol, env).
Back to Top